PharmTech invited Fergus Manford, Vectura’s Intellectual Property patent attorney, to participate with several other experts in a roundtable discussion about the value of engineering particle properties”. The article is focused on particle engineering, a growing trend in the bio/pharma industry, and considers how it can optimise drug development and broaden the range of suitable drug candidates effectively.
“CDMOs offer their clients immediate access to years of expertise and know-how acquired by working with a range of molecules, explains Fergus. Many CDMOs also provide access to proprietary technologies and niche equipment necessary for achieving these optimal formulations, thereby providing a further competitive advantage at a time-critical stage in product development.”
You can read the full article here.